House Bill 1730
116th Congress(2019-2020)
Cancer Drug Parity Act of 2019
Introduced
Introduced in House on Mar 13, 2019
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
1730
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Brian Higgins
grade
New York
Alaska
Arizona
Arizona
Arkansas
Arkansas
California
California
California
California
California
California
California
California
California
California
California
California
California
California
California
California
California
California
California
Colorado
Colorado
Connecticut
Delaware
District of Columbia
Florida
Florida
Florida
Florida
Florida
Florida
Florida
Florida
Florida
Florida
Florida
Florida
Florida
Georgia
Georgia
Georgia
Georgia
Georgia
Hawaii
Illinois
Illinois
Illinois
Illinois
Illinois
Indiana
Indiana
Iowa
Kentucky
Kentucky
Louisiana
Louisiana
Maine
Maryland
Maryland
Maryland
Maryland
Massachusetts
Massachusetts
Massachusetts
Massachusetts
Massachusetts
Massachusetts
Michigan
Michigan
Michigan
Michigan
Michigan
Michigan
Michigan
Michigan
Minnesota
Minnesota
Mississippi
Mississippi
Mississippi
Mississippi
Missouri
Missouri
Missouri
Montana
Nevada
New Hampshire
New Hampshire
New Jersey
New Jersey
New Jersey
New Jersey
New Jersey
New Jersey
New York
New York
New York
New York
New York
New York
New York
New York
New York
New York
New York
New York
New York
New York
North Carolina
North Carolina
North Carolina
North Dakota
Ohio
Ohio
Ohio
Ohio
Ohio
Ohio
Ohio
Ohio
Oklahoma
Oregon
Oregon
Oregon
Pennsylvania
Pennsylvania
Pennsylvania
Pennsylvania
Pennsylvania
Pennsylvania
Pennsylvania
Pennsylvania
Pennsylvania
Pennsylvania
Pennsylvania
South Carolina
Tennessee
Tennessee
Texas
Texas
Texas
Texas
Texas
Texas
Texas
Texas
Texas
Texas
Texas
Texas
Texas
Virginia
Virginia
Virginia
Virginia
Washington
Washington
Washington
Washington
West Virginia
Wisconsin
Wisconsin
Wisconsin
Wisconsin
Wisconsin
Wisconsin
No House votes have been held for this bill.
Summary
Cancer Drug Parity Act of 2019
This bill requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.
To comply with this requirement, health plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.March 13, 2019
03/14/2019
Referred to the Subcommittee on Health.
03/13/2019
Referred to the House Committee on Energy and Commerce.
03/13/2019
Introduced in House
Public Record
Record Updated
Nov 1, 2022 5:47:15 PM